1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2.
By phase and status
Follow BMS-986446: new trials by email Literature Review of BMS-986446 trials Research Report on BMS-986446
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants. BMS-986446, Placebo - Healthy Volunteers Phase 1 Not yet recruiting Bristol-Myers Squibb 10 2027-02-10 2026-10-01 A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration BMS-986446 - Alzheimer's Disease, Healthy Participants Phase 1 Recruiting Bristol-Myers Squibb 84 2026-08-21 2026-09-24 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease BMS-986446, Placebo - Alzheimer Disease, Early Onset Phase 2 Active not recruiting Bristol-Myers Squibb 310 2024-03-20 2025-07-24 A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity BMS-986446, Placebo - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 24 2023-10-12 2024-03-15
Conditions studied Alzheimer Disease (2) · Brain Diseases (1) · Dementia (1) · Neurodegenerative Diseases (1)
Sponsors Bristol-Myers Squibb (4)
Countries United States (3) · Australia (1) · Belgium (1) · Canada (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1)
NIH funding 2023 (1)